OPKO Health’s (OPK) “Outperform” Rating Reiterated at Barrington Research

Barrington Research reaffirmed their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a research note released on Thursday morning,Benzinga reports. The firm currently has a $2.25 target price on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Wednesday, October 8th. Finally, Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $2.28.

OPKO Health Price Performance

Shares of OPK opened at $1.36 on Thursday. OPKO Health has a 12-month low of $1.11 and a 12-month high of $2.04. The business’s fifty day moving average is $1.46 and its 200 day moving average is $1.38. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The stock has a market cap of $1.08 billion, a P/E ratio of -5.44 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $165.74 million. During the same period last year, the business earned $0.03 EPS. OPKO Health’s quarterly revenue was down 12.6% compared to the same quarter last year. Sell-side analysts anticipate that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the stock in a transaction that occurred on Friday, October 31st. The stock was acquired at an average cost of $1.42 per share, with a total value of $213,000.00. Following the transaction, the chief executive officer owned 214,386,448 shares of the company’s stock, valued at $304,428,756.16. This represents a 0.07% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 49.69% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sculptor Capital LP purchased a new stake in shares of OPKO Health during the 1st quarter valued at $21,111,000. Graham Capital Management L.P. increased its position in shares of OPKO Health by 214.7% during the 1st quarter. Graham Capital Management L.P. now owns 1,810,392 shares of the biotechnology company’s stock valued at $3,005,000 after purchasing an additional 3,388,292 shares during the last quarter. Geode Capital Management LLC increased its position in shares of OPKO Health by 23.7% during the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock valued at $13,763,000 after purchasing an additional 1,995,633 shares during the last quarter. Millennium Management LLC increased its position in shares of OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of OPKO Health during the 1st quarter valued at $2,286,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.